净利增速降至个位爱博医疗寄望隐形眼镜业务

Core Viewpoint - Aibo Medical reported a revenue of 787 million yuan for the first half of 2025, marking a year-on-year growth of 14.72%, but showing a decline in growth rate compared to previous years [1] Group 1: Financial Performance - The net profit attributable to shareholders for the first half of 2025 was 213 million yuan, reflecting a year-on-year increase of 2.53% [1] - Aibo Medical's revenue growth rate has slowed down from a consistent 30%+ growth over the past five years, with 2023 and 2024 growth rates at 64.14% and 48.24% respectively [1] - The revenue from artificial lenses, a key product, generated 345 million yuan in the first half of 2025, with a year-on-year growth of 8.23%, but its revenue share decreased from 46.49% in mid-2024 to 43.86% [1] Group 2: Product Segmentation - The contact lens business, which has a stronger consumer attribute, achieved revenue of 236 million yuan during the reporting period, a significant increase of 28.89%, and its share of total revenue rose to 30% [2] - Aibo Medical's contact lens business has seen rapid growth, with revenue jumping from 17.36 million yuan in the first half of 2023 to 183 million yuan in the first half of 2024, marking a 956.92% year-on-year increase [3] - The company has strategically entered the contact lens market by acquiring a 55% stake in Tianyan Pharmaceutical, which specializes in colored contact lenses, in 2021, and has continued to expand production capacity [3]